Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOX-A12 + VD in Relapsed Multiple Myeloma
NCT01521533Phase 2Completed
- Sponsor
- TME Pharma
- Start
- Mar 2012
- Primary completion
- Sep 2014
- Modality
- Polymer-based Nanoparticles, RNA Aptamers, Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of olaptesed pegol in multiple myeloma (MM), sponsored by TME Pharma. Started Mar 2012; status: completed.
02
Drugs
olaptesed pegol
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01521533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01521533.